RB
Rahul D. Ballal
Director

Rahul D. Ballal insider trades: Agios Pharmaceuticals (AGIO) stock sales

Director, Agios Pharmaceuticals Last trade Nov 8, 2024 25 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2020
3
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Rahul reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 8, 2024AGIO↓ Sell$1.1M
Oct 8, 2024ELVN↓ Sell$294K
Apr 11, 2024ELVN↓ Sell$1.6M
Apr 4, 2024ELVN↓ Sell$67K
Apr 1, 2024ELVN↓ Sell$62K
Mar 20, 2024ELVN↓ Sell$254K
Feb 22, 2023IMRA↓ Sell$153K
Jan 30, 2023IMRA↓ Sell$44K
Dec 17, 2020IMRA↓ Sell$125K
Dec 14, 2020IMRA↓ Sell$25

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AGIO insiders

Open-market trades in the last 12 months

About Rahul D. Ballal's insider trades

Rahul D. Ballal is a director at Agios Pharmaceuticals (AGIO). Since Dec 14, 2020, Rahul has reported no open-market purchases and 10 sales worth $3.7M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include option exercises (14 filings), grants and awards (11 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.